Intellectual Property India Publishes Patent Application for 10,11-Difluoro-12-((2-Fluoro-4-Iodophenyl)amino)-5,6-Dihydroxy-4,5,6,7-Tetrahydro-1h- Spiro[benzo[b][1,5,4]oxathiazecine-3,1'-Cyclopropane] 2,2-Dioxide Stereoisomers, And Compositions Comprising And Methods Of Using The Same

MUMBAI, India, Aug. 12 -- Intellectual Property India has published a patent application (202647091912 A) filed by Pasithea Therapeutics Corp. on July 29, 2026, for 10,11-Difluoro-12-((2-Fluoro-4-Iodophenyl)amino)-5,6-Dihydroxy-4,5,6,7-Tetrahydro-1h- Spiro[benzo[b][1,5,4]oxathiazecine-3,1'-Cyclopropane] 2,2-Dioxide Stereoisomers, And Compositions Comprising And Methods Of Using The Same.

Inventors include Lazarus, Mathew; Marques, Tiago, Reis; and Khire, Uday.

The application for the patent was published on August 07, 2026, under issue no. 32/2026.

Abstract: Described herein are 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6- dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2- dioxide stereoisomer compounds and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a disease or disorder in which the RAS pathway is upregulated such as cancer, RASopathies and laminopathies.

Disclaimer: Curated by HT Syndication.